Although the incidence rate of @entity981 ( @entity981 ) is slightly higher in older than in younger adults, response rates to induction chemotherapy and survival rates are poorer. The contribution of disease-related versus treatment-related factors remains unclear. We analysed 100 older @entity1 (aged 55-65  years) treated on the UKALLXII/ECOG2993 trial compared with 1814 younger @entity1 (aged 14-54  years). Baseline characteristics, induction chemotherapy course, @entity281 , drug reductions and survival outcomes were compared. There were more Philadelphia-positive (Ph+) @entity1 in the older group (28% vs. 17%, P  =  0  02), and a trend towards higher combined cytogenetic risk score (46% vs. 35%, P  =  0  07). The complete remission rate in older @entity1 was worse (73% vs. 93%, P  <  0  0001) as was 5-year overall survival (21% vs. 41%, P  <  0  0001) and event-free survival (EFS) (19% vs. 37%, P  <  0  0001). Older @entity1 had more @entity281 during induction (81% vs. 70%, P  =  0  05), and drug reductions (46% vs. 28%, P  =  0  0009). Among older @entity1 , Ph+ and cytogenetic risk category as well as infection during induction predicted for worse EFS. Poorer outcomes in these @entity1 are partly due to cytogenetic risk, but there is significant morbidity and mortality during induction chemotherapy with frequent delays and drug reductions. New approaches, including better risk stratification and use of targeted therapies, could improve treatment for these @entity1 .

Outcomes in older adults with XXXX ( @entity981 ): results from the international MRC UKALL XII/ECOG2993 trial.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity281 :: ('MESH:D007239', 'Disease') :: ['infections'] @entity981 :: ('MESH:D054198', 'Disease') :: ['ALL', 'acute lymphoblastic leukaemia']
@entity981 :: (MESH:D054198,Disease) :: ['acute lymphoblastic leukaemia']
